As a domestic CDMO service provider with a CGMP production site in the United States, BIOLOGICAL PHARMA CENTER Bio’s US manufacturing facility is equipped with bioreactors’ production capacity of 1000 L and 2 × 500 L.�  BIOLOGICAL PHARMA CENTER Bio US plant has accumulated vast experience in protein drugs large-scale production, operation, and management. At the same time in China, BIOLOGICAL PHARMA CENTER Bio has built production facility to meet the 2 × 200 L, 2 × 500 L manufacturing scale and supporting Process Development activities. BIOLOGICAL PHARMA CENTER Bio plans to build a production facility with 100,000-liter manufacturing capability for BDS (bulk drug substance) in China that meets the GMP standards of China, the United States, and the European Union. The production facilities and experienced teams in the United States and China and will support biopharmaceutical companies to achieve dual registration in these two countries and strategically plan multi-region manufacturing.